# Safety and Efficacy of Alogliptin in Indian Participants With Type 2 Diabetes Mellitus

> **NCT03042325** · PHASE4 · WITHDRAWN · sponsor: **Takeda**

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Alogliptin

## Key facts

- **NCT ID:** NCT03042325
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-07-30
- **Primary completion:** 2018-01-15
- **Final completion:** 2018-01-15
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Business decision, no safety or efficacy concerns
- **Last updated:** 2017-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03042325

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03042325, "Safety and Efficacy of Alogliptin in Indian Participants With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03042325. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*